Activators of the unfolded protein response

Paul Hergenrother; David J Shapiro; Matthew Wesley Boudreau

Activators of the unfolded protein response

Paul Hergenrother (Inventor), David J Shapiro (Inventor), Matthew Wesley Boudreau (Inventor)

Research output: Patent

Abstract

A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.

Original language	English (US)
U.S. patent number	11046647
Filing date	2/26/20
State	Published - Jun 29 2021

Library availability

Discover UIUC Full Text

Cite this

@misc{b4927fcb9ba343d69cee24c3547763d6,

title = "Activators of the unfolded protein response",

abstract = "A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.",

author = "Paul Hergenrother and Shapiro, {David J} and Boudreau, {Matthew Wesley}",

note = "GOVERNMENT SUPPORT This invention was made with government support under Grant No. RO1 DK071909 awarded by the National Institutes of Health and W81XWH-14-1-0159 awarded by the United States Army. The government has certain rights in the invention. ; 11046647",

year = "2021",

month = jun,

day = "29",

language = "English (US)",

type = "Patent",

}

TY - PAT

T1 - Activators of the unfolded protein response

AU - Hergenrother, Paul

AU - Shapiro, David J

AU - Boudreau, Matthew Wesley

N1 - GOVERNMENT SUPPORT This invention was made with government support under Grant No. RO1 DK071909 awarded by the National Institutes of Health and W81XWH-14-1-0159 awarded by the United States Army. The government has certain rights in the invention.

PY - 2021/6/29

Y1 - 2021/6/29

N2 - A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.

AB - A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.

M3 - Patent

M1 - 11046647

Y2 - 2020/02/26

ER -

Activators of the unfolded protein response

Abstract

Library availability

Fingerprint

Cite this